xRead - September 2022

Wise et al.

Page 388

Author Manuscript Author Manuscript Author Manuscript Author Manuscript TABLE IX.B.6. Clinical

endpoint Conclusion

Rhinorrhea Combined use of IPB with BDP is more effective than either agent alone for controlling rhinorrhea.

Nasal symptoms Control of rhinorrhea and sneezing better in IPB + terbinafine. No differences in nasal congestion.

Nasal symptoms High-dose and low-dose IPB resulted in significant reduction of nasal hypersecretion vs placebo. Nasal symptoms, medication use, QOL

In perennial NAR, IPB reduced symptoms. In PAR, a modest effect was seen.

IPB resulted in a decrease in albumin, total protein, eosinophil count, and an increase in nasal reactivity to histamine with an increase in the number of sneezes.

IPB is effective in controlling rhinorrhea. No differences in other outcomes.

Nasal symptoms IPB has suppressive effects on sneezing and hypersecretion, but no influence on nasal airway resistance.

Sneezing,

albumin and total protein in nasal lavage

Nasal symptoms, nasal cytology

1 IPB 0.03%, 2 sprays (42 μ g) TID + BDP 82 μ g BID (n = 109);

1 IPB 21 μ g (n = 48) or 42 μ g (n = 54), 1 spray TID; 2 Placebo (n = 53)

Evidence for the use of ipratropium bromide in the treatment of allergic rhinitis Study Year LOE Study design Study groups Dockhorn et al. 1381 1999 1b DBRCT PAR, 8–75 years old: 2 IPB 0.03%, 2 sprays (42 μ g) TID (n = 222); 3 BDP 82 μ g BID (n = 222); 4 Placebo (n = 55) Finn et al. 1382 1998 1b DBRCT, crossover PAR, 18–75 years old (n = 205): 1 IPB 0.03% (42 μ g) TID + terfenadine 60 mg PO BID; 2 Placebo + terfenadine Kaiser et al. 1379 1998 1b DBRCT PAR, adults: 1 IPB 0.03% (42 μ g) TID; 2 IPB 0.06% (84 μ g) TID; 3 Placebo

Meltzer et al. 1383 1997 1b DBRCT PAR and perennial NAR, 6–18 years old: 1 IPB 0.03% 2 sprays (42 μ g) BID (n = 102); 2 Placebo (n = 102)

Gorski et al. 1384 1993 1b DBRCT PAR, 23–33 years old (n = 18): 1 IPB 80 μ g QID; 2 Placebo

SAR or PAR (n = 14), non-allergic perennial rhinitis (n = 10), 18-49 years old: 1 IPB 80 μ g QID;

Meltzer et al. 1385 1992 1b DBRCT PAR, 18–70 years old:

crossover

1986 1b DBRCT,

Sanwikarja et al. 1386

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.